Stockholm - Delayed Quote SEK

Hansa Biopharma AB (publ) (HNSA.ST)

Compare
21.70
-0.94
(-4.15%)
At close: 5:29:46 PM GMT+2
Currency in SEK All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
171,316
171,316
134,094
154,525
33,878
Cost of Revenue
83,554
83,554
63,143
38,477
15,425
Gross Profit
87,762
87,762
70,951
116,048
18,453
Operating Expense
725,136
725,136
859,447
692,168
558,033
Operating Income
-637,374
-637,374
-788,496
-576,120
-539,580
Net Non Operating Interest Income Expense
-166,331
-166,331
-42,316
-34,833
-627
Pretax Income
-803,705
-803,705
-830,812
-609,979
-548,130
Tax Provision
3,034
3,034
908
1,155
152
Net Income Common Stockholders
-806,739
-806,739
-831,720
-611,134
-548,282
Diluted NI Available to Com Stockholders
-806,739
-806,739
-831,720
-611,134
-548,282
Basic EPS
-11.03
-12.84
-15.83
-13.60
-12.33
Diluted EPS
-11.03
-12.84
-15.83
-13.60
-12.33
Basic Average Shares
59,040.51
62,834.85
52,540.09
44,924
44,473.45
Diluted Average Shares
59,040.51
62,834.85
52,540.09
44,924
44,473.45
Total Operating Income as Reported
-634,344
-634,344
-488,496
-588,588
-546,978
Total Expenses
808,690
808,690
922,590
730,645
573,458
Net Income from Continuing & Discontinued Operation
-806,739
-806,739
-831,720
-611,134
-548,282
Normalized Income
-806,739
-806,739
-831,720
-607,185.44
-547,865.15
Interest Income
20,834
20,834
63,204
8,833
67
Interest Expense
187,165
187,165
105,520
43,666
694
Net Interest Income
-166,331
-166,331
-42,316
-34,833
-627
EBIT
-616,540
-616,540
-725,292
-566,313
-547,436
EBITDA
-616,540
-616,540
-725,292
-554,259
-538,830
Reconciled Cost of Revenue
83,554
83,554
63,143
38,477
15,425
Reconciled Depreciation
--
--
19,792
12,054
8,606
Net Income from Continuing Operation Net Minority Interest
-806,739
-806,739
-831,720
-611,134
-548,282
Total Unusual Items Excluding Goodwill
-525
--
70
-4,973
-525
Total Unusual Items
-525
--
70
-4,973
-525
Normalized EBITDA
-616,540
-616,540
-725,292
-549,286
-538,305
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
--
--
--
-1,024.44
-108.15
12/31/2021 - 10/17/2007

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CANTA.ST Cantargia AB (publ)
1.2950
-2.04%
 
ACE.ST Ascelia Pharma AB (publ)
2.5500
-4.49%
 
XBRANE.ST Xbrane Biopharma AB (publ)
0.1800
-4.66%
 
FLUI.ST Fluicell AB (publ)
11.66
-14.89%
 
COMBI.ST CombiGene AB (publ)
2.3500
-1.26%
 
IMMU.ST Mendus AB (publ)
5.70
+2.46%
 
ONCO.ST Oncopeptides AB (publ)
1.6660
-2.34%
 
XSPRAY.ST Xspray Pharma AB (publ)
26.05
-9.86%
 
KAN.ST Kancera AB (publ)
1.1020
-1.61%
 
ELIC.ST Elicera Therapeutics AB (publ)
2.9200
-1.02%